Table 4.
Study | Tumor characteristics | Imaging modality | Outcome | Machine learning methods |
---|---|---|---|---|
Shen et al. 2020 108 | NPC | MRI | PFS | LASSO |
Xu et al. 2020 113 | NPC | PET | PFS | / |
Ouyang et al. 2017 114 | NPC | MRI | PFS | / |
Zhang et al. 2017 115 | Advanced NPC | MRI | PFS | LASSO |
Lv et al. 2019 53 | NPC | PET | PFS | / |
Peng et al. 2019 52 | NPC | PET | DFS | Deep learning |
Yuan et al. 2019 109 | HNSCC | MRI | OS | LASSO |
Ming et al. 2019 116 | NPC | MRI | DFS, OS, LRFS, DMFS | LASSO |
Mao et al. 2019 117 | NPC | MRI | PFS | / |
Chen et al. 2020 118 | LC | CT | OS | LASSO |
Folkert et al.2017 119 | OC | PET | ACM, DM | Multiparameter logistic regression |
Foley et al.2018 120 | OC | PET | OS | / |
Chen et al.2019 121 | EC | PET | DFS, OS | Multivariate logistic regression |
Xiong et al. 2017 122 | EC | PET | PFS | SVM, RF |
Feliciani et al. 2018 123 | HNC | PET | PFS | LASSO |
Liao et al. 2019 124 | Oropharyngeal and hypopharyngeal cancer | PET | OS, PRFS, DFS | / |
Lv et al. 2019 125 | HNC | PET/CT | RFS, MFS, OS | / |
Yang et al. 2019 126 | Advanced NPC | MRI | PFS | LASSO |
Leijenaar et al. 2015 127 | OSCC | CT | OS | / |
Agarwal et al. 2020 111 | LC | CT | LFS | / |
Zhong et al. 2020 128 | T3N0M0 NPC | MRI | DFS | Deep learning |
Parmar et al. 2015 110 | HNC | CT | OS | Different machine-learning classifiers |
Liu et al. 2020 112 | HNSCC | PET | OS, DFS | / |
Pan et al. 2019 130 | Oral tongue cancer | CT | Survival time | PCA |
Xie et al. 2020 129 | HNC | PET | OS, DFS | LR, SVM, RF, XG boost classifier |
Cozzi et al. 2019 131 | HNC | CT | OS, PFS | / |
Legar et al. 2018 132 | HNC | CT | OS, LRC | Six machine learning algorithms |
Sörensen et al. 2019 133 | HNC | PET | OS | / |
Haider et al. 2020 134 | OSCC | PET | OS, PFS | / |
Ou et al. 2017 135 | HNC | CT | PFS, OS | PCA |
Miller et al. 2019 136 | OPSCC | CT | PFS | / |
Mes et al. 2020 137 | HNSCC | MRI | RFS, OS | / |
OPSCC: Oropharyngeal Squamous Cell Carcinoma; RFS: Relapse-free survival; ACM: All-cause mortality; LFS: Laryngectomy free survival; PRFS: Primary relapse-free survival; RFS: Recurrence-free survival; MFS: Metastasis-free survival; LRC: Locoregional tumor control; DMFS: Disease distant metastasis-free survival; OC: Oropharyngeal carcinoma.